Literature DB >> 29478864

Management of Acute Kidney Injury: Core Curriculum 2018.

Peter K Moore1, Raymond K Hsu2, Kathleen D Liu3.   

Abstract

Acute kidney injury (AKI) is a heterogeneous disorder that is common in hospitalized patients and associated with short- and long-term morbidity and mortality. When AKI is present, prompt workup of the underlying cause should be pursued, with specific attention to reversible causes. Measures to prevent AKI include optimization of volume status and avoidance of nephrotoxic medications. Crystalloids are preferred over colloids for most patients, and hydroxyethyl starches should be avoided. Volume overload in the setting of AKI is associated with adverse outcomes, so attention should be paid to overall fluid balance. Currently there are no targeted pharmacotherapies approved for the treatment of AKI. The optimal timing of renal replacement therapy in critically ill patients with AKI is unclear, but is an area of active investigation. Recent studies suggest that AKI is not a "self-limited" process, but is strongly linked to increased risk for chronic kidney disease, subsequent AKI, and future mortality.
Copyright © 2018 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AKIN; Acute kidney injury (AKI); KDIGO; RIFLE; critical care; fluid balance; intrarenal; postrenal; prerenal; renal replacement therapy (RRT); review; serum creatinine (Scr); treatment; urine output; volume status

Mesh:

Year:  2018        PMID: 29478864     DOI: 10.1053/j.ajkd.2017.11.021

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  50 in total

1.  Quality of care after AKI development in the hospital: Consensus from the 22nd Acute Disease Quality Initiative (ADQI) conference.

Authors:  Etienne Macedo; Azra Bihorac; Edward D Siew; Paul M Palevsky; John A Kellum; Claudio Ronco; Ravindra L Mehta; Mitchell H Rosner; Michael Haase; Kianoush B Kashani; Erin F Barreto
Journal:  Eur J Intern Med       Date:  2020-06-30       Impact factor: 4.487

2.  Vitamin C Deficiency Causes Cell Type-Specific Epigenetic Reprogramming and Acute Tubular Necrosis in a Mouse Model.

Authors:  Zihui Yu; Ziying Xu; Yuan Liang; Pengbin Yin; Yue Shi; Jiayi Yu; Junfeng Hao; Ting Wang; Weimin Ci
Journal:  J Am Soc Nephrol       Date:  2022-01-04       Impact factor: 10.121

Review 3.  Novel Drug Delivery Technologies and Targets for Renal Disease.

Authors:  Alejandro R Chade; Gene L Bidwell
Journal:  Hypertension       Date:  2022-06-02       Impact factor: 9.897

Review 4.  Overview of Diagnostic Criteria and Epidemiology of Acute Kidney Injury and Acute Kidney Disease in the Critically Ill Patient.

Authors:  Bethany C Birkelo; Neesh Pannu; Edward D Siew
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-15       Impact factor: 10.614

Review 5.  Targeting immune cell metabolism in kidney diseases.

Authors:  Paulo José Basso; Vinicius Andrade-Oliveira; Niels Olsen Saraiva Câmara
Journal:  Nat Rev Nephrol       Date:  2021-04-07       Impact factor: 28.314

6.  Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?

Authors:  Nakyung Jeon; Haesuk Park; Richard Segal; Babette Brumback; Almut G Winterstein
Journal:  Eur J Clin Pharmacol       Date:  2021-03-27       Impact factor: 2.953

7.  The role and mechanism of PKM2 in the development of LPS-induced acute kidney injury.

Authors:  Jiajun Wu; Shu Rong; Jing Zhou; Weijie Yuan
Journal:  Histol Histopathol       Date:  2021-05-12       Impact factor: 2.303

Review 8.  INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease.

Authors:  Anil Arora; Ashish Kumar; Narayan Prasad; Ajay Duseja; Subrat K Acharya; Sanjay K Agarwal; Rakesh Aggarwal; Anil C Anand; Anil K Bhalla; Narendra S Choudhary; Yogesh K Chawla; Radha K Dhiman; Vinod K Dixit; Natarajan Gopalakrishnan; Ashwani Gupta; Umapati N Hegde; Sanjiv Jasuja; Vivek Jha; Vijay Kher; Ajay Kumar; Kaushal Madan; Rakhi Maiwall; Rajendra P Mathur; Suman L Nayak; Gaurav Pandey; Rajendra Pandey; Pankaj Puri; Ramesh R Rai; Sree B Raju; Devinder S Rana; Padaki N Rao; Manish Rathi; Vivek A Saraswat; Sanjiv Saxena; Praveen Sharma; Shivaram P Singh; Ashwani K Singal; Arvinder S Soin; Sunil Taneja; Santosh Varughese
Journal:  J Clin Exp Hepatol       Date:  2020-10-09

9.  Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) protects against renal ischemia/reperfusion injury by inhibiting inflammation.

Authors:  A-Feng Miao; Jian-Xiang Liang; Lei Yao; Jun-Ling Han; Li-Juan Zhou
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

10.  Quality Improvement Goals for Acute Kidney Injury.

Authors:  Kianoush Kashani; Mitchell Howard Rosner; Michael Haase; Andrew J P Lewington; Donal J O'Donoghue; F Perry Wilson; Mitra K Nadim; Samuel A Silver; Alexander Zarbock; Marlies Ostermann; Ravindra L Mehta; Sandra L Kane-Gill; Xiaoqiang Ding; Peter Pickkers; Azra Bihorac; Edward D Siew; Erin F Barreto; Etienne Macedo; John A Kellum; Paul M Palevsky; Ashita Jiwat Tolwani; Claudio Ronco; Luis A Juncos; Oleksa G Rewa; Sean M Bagshaw; Theresa Ann Mottes; Jay L Koyner; Kathleen D Liu; Lui G Forni; Michael Heung; Vin-Cent Wu
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.